{"id":"nct:NCT07307053","kind":"trial","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","authors":["Cancer Institute and Hospital, Chinese Academy of Medical Sciences"],"author_count":1,"year":2025,"published":"2025-12-29","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07307053","source_url":"https://clinicaltrials.gov/study/NCT07307053","archive_url":"https://space-kitty.com/papers/nct:NCT07307053","updated":"2025-12-29","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The goal of this Phase I/II observational and interventional platform study is to evaluate the safety and efficacy of multiple types of innovative anti-tumor drugs and new technologies in patients with rare solid tumors. The study utilizes multi-dimensional precision screening (including WES, RNAseq, mIHC, and quantitative proteomics) to match patients with specific sub-protocols. Key questions it aims to answer: Assess the safety of innovative therapies in rare tumor populations. Evaluate the objective response rate (ORR) and other efficacy metrics. Explore biomarkers related to therapeutic efficacy. Participants: Patients with metastatic or advanced rare solid tumors who have failed standard therapy or have no standard treatment options.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Rare Malignant Neoplasm","Advanced Solid Tumors","Metastatic Solid Tumors"],"details":{"acronym":null,"status":"NOT_YET_RECRUITING","phase":"PHASE1, PHASE2","study_type":"INTERVENTIONAL","enrollment":600,"sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","conditions":["Rare Malignant Neoplasm","Advanced Solid Tumors","Metastatic Solid Tumors"],"interventions":["DRUG: BL-B01D1","DRUG: VSV injection","DRUG: CVL006","BIOLOGICAL: IDOV-SAFE","BIOLOGICAL: KXV01 TCR Lentinvivo Injection","BIOLOGICAL: MT027","BIOLOGICAL: QH101","BIOLOGICAL: Meta10-TIL","BIOLOGICAL: TAEST1901","BIOLOGICAL: TC-N201"],"start_date":"2026-01-01","start_date_type":"ESTIMATED","primary_completion_date":"2029-01-31","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"mrna-cancer-vaccines","name":"mRNA Therapeutics & Cancer Vaccines","domain_slug":"medicine"}],"cited_in_dossiers":[]}